Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma-Reference-Cited by-同舟云学术

Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma

Published:2021-01-01 Issue:1 Volume:26 Page:945-949
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Kamiya Takahiro¹^ORCID,Sakurai Masatoshi¹,Kikuchi Taku¹,Okayama Mikio¹,Mizuno Kota¹,Tanigawa Tomohiko¹,Koda Yuya¹,Kato Jun¹,Mori Takehiko¹

Affiliation:

1. Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2021.2001150

Reference27 articles.

1. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea

2. Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control

3. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer

4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Antiemesis. version 2. (2020). Available from: https://www.nccn.org/professionals/physician_gls/pdf/ antiemesis.pdf. Accessed June 7, 2020.

5. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting;Journal of Cancer Research and Clinical Oncology;2024-06-05

2. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study);eClinicalMedicine;2023-01

3. The efficacy of single dose palonosetron in highly emetogenic chemotherapy protocols compared to oral aprepitant and ondansetron;Journal of Pharmacovigilance and Drug Research;2022-09-01